Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Company research

BioPlus Acquisition Corp.

CIK 1856653Updated Sep 24, 2026

BIOS price & chart

Provider market data
Historical security

This listing closed Oct 6, 2023. Live provider charts are shown only for current listings.

In the news

No coverage from other publishers is available.

Recent filings

  1. SC 13G/A filing

    SC 13G/A · 2024-02-07 · 0001062993-24-002220

  2. 15-12G filing

    15-12G · 2023-10-16 · 0001013762-23-004114

  3. 25-NSE filing

    25-NSE · 2023-10-06 · 0001354457-23-000730

  4. RW filing

    RW · 2023-10-04 · 0001193125-23-250350

  5. 8-K filing

    8-K · 2023-10-04 · 0001013762-23-001374

Show 5 more recent filings
  1. 425 filing

    425 · 2023-09-15 · 0001193125-23-236139

  2. 425 filing

    425 · 2023-08-16 · 0001193125-23-213941

  3. 10-Q filing

    10-Q · 2023-08-14 · 0001193125-23-212329

  4. S-4/A filing

    S-4/A · 2023-08-01 · 0001193125-23-200618

  5. 425 filing

    425 · 2023-07-17 · 0001193125-23-187699

Financials

FY 2022 · USD
Revenue · FY 2022
Net income · FY 2022
Cash · FY 2022
Operating income · FY 2022
Diluted EPS · FY 2022

Some figures are unavailable for this reporting year.

balance sheet · annual statements
Line itemFY 2022FY 2021
ASSETS
AssetsUSD238,324,586
Source

10-K · 2023-03-31 · 0001193125-23-087738

As of 2022-12-31

235,980,915
Source

10-K · 2022-03-11 · 0001193125-22-073378

As of 2021-12-31

Current assets:
Cash and Cash Equivalents, at Carrying ValueUSD635,542
Source

10-K · 2022-03-11 · 0001193125-22-073378

As of 2021-12-31

Assets, CurrentUSD548,763
Source

10-K · 2023-03-31 · 0001193125-23-087738

As of 2022-12-31

1,002,286
Source

10-K · 2022-03-11 · 0001193125-22-073378

As of 2021-12-31

LIABILITIES AND EQUITY
LiabilitiesUSD15,326,875
Source

10-K · 2023-03-31 · 0001193125-23-087738

As of 2022-12-31

14,979,136
Source

10-K · 2022-03-11 · 0001193125-22-073378

As of 2021-12-31

Stockholders’ equity:
Retained Earnings (Accumulated Deficit)USD-14,778,743
Source

10-K · 2023-03-31 · 0001193125-23-087738

As of 2022-12-31

13,598,852
Source

10-K · 2022-03-11 · 0001193125-22-073378

As of 2021-12-31

Stockholders' Equity Attributable to ParentUSD-14,778,112
Source

10-K · 2023-03-31 · 0001193125-23-087738

As of 2022-12-31

-13,598,221
Source

10-K · 2022-03-11 · 0001193125-22-073378

As of 2021-12-31

Liabilities and EquityUSD238,324,586
Source

10-K · 2023-03-31 · 0001193125-23-087738

As of 2022-12-31

235,980,915
Source

10-K · 2022-03-11 · 0001193125-22-073378

As of 2021-12-31

Current liabilities:
Liabilities, CurrentUSD526,875
Source

10-K · 2023-03-31 · 0001193125-23-087738

As of 2022-12-31

179,136
Source

10-K · 2022-03-11 · 0001193125-22-073378

As of 2021-12-31

Additional Financial Items
Accrued Liabilities, CurrentUSD263,150
Source

10-K · 2023-03-31 · 0001193125-23-087738

As of 2022-12-31

111,636
Source

10-K · 2022-03-11 · 0001193125-22-073378

As of 2021-12-31

Lines labelled “Derived” are calculated from reported figures.

cash flow · annual statements
Line itemFY 2022FY 2021
Cash flows from operating activities:
Net Cash Provided by (Used in) Operating ActivitiesUSD-691,465
Source

10-K · 2023-03-31 · 0001193125-23-087738

2022-01-01 to 2022-12-31

-773,937
Source

10-K · 2022-03-11 · 0001193125-22-073378

2021-02-11 to 2021-12-31

Cash flows from investing activities:
Net Cash Provided by (Used in) Investing ActivitiesUSD0
Source

10-K · 2023-03-31 · 0001193125-23-087738

2022-01-01 to 2022-12-31

-234,600,000
Source

10-K · 2022-03-11 · 0001193125-22-073378

2021-02-11 to 2021-12-31

Cash flows from financing activities:
Net Cash Provided by (Used in) Financing ActivitiesUSD196,225
Source

10-K · 2023-03-31 · 0001193125-23-087738

2022-01-01 to 2022-12-31

236,009,479
Source

10-K · 2022-03-11 · 0001193125-22-073378

2021-02-11 to 2021-12-31

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD-495,240
Source

10-K · 2023-03-31 · 0001193125-23-087738

2022-01-01 to 2022-12-31

Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD140,302
Source

10-K · 2023-03-31 · 0001193125-23-087738

As of 2022-12-31

Additional Financial Items
Net Income (Loss) Attributable to ParentUSD1,995,932
Source

10-K · 2023-03-31 · 0001193125-23-087738

2022-01-01 to 2022-12-31

-140,200
Source

10-K · 2022-03-11 · 0001193125-22-073378

2021-02-11 to 2021-12-31

Proceeds from Issuance of Common StockUSD25,000
Source

10-K · 2022-03-11 · 0001193125-22-073378

2021-02-11 to 2021-12-31

Lines labelled “Derived” are calculated from reported figures.